Member Info for Scarabbeatle

A slight retrace followed by a slight gain. Imo.

Going to be a good day

Trust me mate, putting the ppe on to go into a barrier patient room is not somthing I would/relish doing any more than I have too, I am not clinical staff but never the less still have to come into contact daily with these situations. Hurry up and get sng approved.

The Indian sub continent as a whole is a cause of concern, (Pakistan Bangladesh) the later being more densely populated. The faster the tests, and treatment can get there the better for humanity

I think both have their individual strengths. I invested in Avct due to their affirmers, here due to the portability of their testing. There is plenty of space in the market for both. And will be of interest to see how they work with cytiva. Imo. I want both to work and get rid of this awful situation the world is in atm.

Remember both GDR and AVCT have tie ins with cytiva. Is this just for the individual tech or somthing else going on behind the scenes. So may not be working against each other IMO.

Somthing I am curious over is that avct and gdr both have tie ins with cytiva. Is this on separate testing methods or is somthing else being collaborated. It would be interesting to find out tbh. Imo. As both companies have interesting tech which could be intertwined maybe??.

Everyone is here for the benefit of a fantastic opportunity to invest in somthing that can help in the fight of c19. Please don't let this bb turn into a slanging match ??

Just remember key NHS workers have to have symptoms before they can can go for a test.

6 months £2
12 months £5 ish
If everything works out.

I would be more than happy considering the millions that would of been helped

Plenty of advice there pal, and it is good neutral advice. Which is lucky on any bb. Take what you want but be happy with any decision you take

Caution always, money means different to different people dependant on how much you have, my belief is you could get rich quick off this but it does offer a long term investment. I have been here from 40p. And am looking to add more next week. DYOR this is my opinion. All the best with your decision.

I have seen you on sng, you seem sensible and a well balanced investor. Now consider the fact of the lack of reagents in the world. Increase of testing required to get the world back to some sort of normality. Plus the chemo arm of the company. In my opinion this is a safe bet as safe as any Aim market share can be. It has a massive US backer and is developing new tech. Defiantly on a retrace but as everyone says DYOR. And be happy with your decision. Hope it helps

Unsure of exact end of the trial, but in the scope there is a 14 day treatment course per patient. however the existing trial can be expanded into a phase 3 trial or become apart of the government led trials. This is my opinion based on links previously discussed. So that date to some extent is irrelevant.

This study was carried out in 2014. Interesting outcomes and hopefully would mirror the results in this trial
American Journal of Respiratory and Critical Care Medicine
The Effect of Inhaled IFN-ß on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
Ratko Djukanovic, Tim Harrison, [...], and Phillip Monk
In summary, this study suggests for the first time that administration of IFN-ß by inhalation can enhance innate immunity both locally within the lungs and, to a lesser extent, systemically, thereby compensating for the IFN-ß deficiency that we have previously demonstrated ex vivo in the epithelium of patients with moderate-severe asthma (6). The possible beneficial clinical effect of treatment seen in patients with moderate-severe asthma that was associated with this enhancement suggests that this treatment may impact favorably on cold-induced asthma exacerbations. The trial was designed and powered on the basis of the entire mITT patient population; therefore, further adequately powered studies focusing on more difficult-to-treat people with asthma are now needed to test the hypothesis that IFN-ß is effective in this high-risk patient population.

Footnotes
Supported by Synairgen Research Limited, a University of Southampton spinout company.

Always down over the weekend. Will only know on Tuesday when they have caught up. imho

Testing will still be key, if you trst possitive you would isolate then through contact tracing would test those who have come into Contact with you while you are shedding the virus. Testing is a fundamental step along with any form of treatment to get the economy back up and running again.

Very true LP, I believe in this therapy and really hope it works, my mrs and our family work on the front line, if this works as much as I hope, it could save so many lives and families mine included.

If it drops from 62 to 56 striaghgt away, your shares will be sold probably at bottom value dependant on who you are with.

If you sell too early you will risk being locked out if it bounces straight away.